Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TOM1-like protein 2 (TOM1L2) is a human adaptor protein encoded by the TOM1L2 gene. It contains an N-terminal VHS domain, a GAT domain, and a C-terminal clathrin-binding motif, enabling TOM1L2 to participate in vesicular trafficking and endosomal sorting. TOM1L2 plays a critical role in ciliary signaling by acting as an adaptor for Lys63-linked ubiquitin chains and the BBSome complex, facilitating the removal of ubiquitinated G protein-coupled receptors from cilia. It colocalizes with Golgi compartments and is believed to regulate growth factor-mediated signaling and immune response. Genetic variants in TOM1L2 are implicated in musculoskeletal traits and disease syndromes such as Smith-Magenis syndrome. Knockdown or loss of TOM1L2 in animal models leads to increased susceptibility to infections, tumor development, splenomegaly, abnormal B- and T-cell counts, and impaired humoral immune responses.
Not established; theoretically, drugs influencing TOM1L2 would affect vesicular trafficking, GPCR signaling, and immune response modulation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on TOM1-like protein 2 (TOM1L2).